Immix Biopharma (NASDAQ:IMMX) Posts Quarterly Earnings Results, Beats Estimates By $0.06 EPS

Immix Biopharma (NASDAQ:IMMX) posted its earnings results on Monday. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.06, Zacks reports.

Immix Biopharma Trading Up 0.5 %

NASDAQ IMMX traded up $0.01 on Wednesday, hitting $1.87. 33,026 shares of the company’s stock were exchanged, compared to its average volume of 205,373. The stock has a 50-day moving average of $2.10 and a 200-day moving average of $2.53. Immix Biopharma has a 52 week low of $1.55 and a 52 week high of $7.75. The stock has a market cap of $49.39 million, a price-to-earnings ratio of -2.00 and a beta of 0.17.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $7.00 price target on shares of Immix Biopharma in a research note on Friday, July 26th.

Immix Biopharma Company Profile

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.